A461030 Stock Overview

Provides liquid biopsy platform in South Korea. More details

A461030 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Volatile share price over the past 3 months compared to the KR market

My Notes

Capture your thoughts, links and company narrative

IMB Dx, Inc. Competitors

MedPacto

KOSDAQ:A235980

₩151.6b

Qurient

KOSDAQ:A115180

₩158.0b

DNA Link

KOSDAQ:A127120

₩126.4b

ISU Abxis

KOSDAQ:A086890

₩159.0b

Price History & Performance

Summary of share price highs, lows and changes for IMB Dx
Historical stock prices
Current Share Price	₩11,000.00
52 Week High	₩40,550.00
52 Week Low	₩8,430.00
Beta	0
1 Month Change	-2.74%
3 Month Change	-37.03%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-69.44%

Recent updates

Shareholder Returns

	A461030	KR Biotechs	KR Market
7D	7.6%	1.5%	-1.5%
1Y	n/a	3.9%	-10.9%

Return vs Industry: Insufficient data to determine how A461030 performed against the KR Biotechs industry.

Return vs Market: Insufficient data to determine how A461030 performed against the KR Market.

Price Volatility

Is A461030's price volatile compared to industry and market?
A461030 volatility
A461030 Average Weekly Movement	10.5%
Biotechs Industry Average Movement	8.8%
Market Average Movement	6.6%
10% most volatile stocks in KR Market	12.8%
10% least volatile stocks in KR Market	3.4%

Stable Share Price: A461030's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A461030's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

Founded	Employees	CEO	Website
2018	n/a	Tae-You Kim	www.imbdx.com

IMB Dx, Inc. provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test. The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer early detection.

IMB Dx, Inc. Fundamentals Summary

How do IMB Dx's earnings and revenue compare to its market cap?
A461030 fundamental statistics
Market cap	₩154.20b
Earnings (TTM)	₩0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is A461030 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A461030 income statement (TTM)
Revenue	₩0
Cost of Revenue	₩0
Gross Profit	₩0
Other Expenses	₩0
Earnings	₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did A461030 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/02 01:43
End of Day Share Price	2025/01/02 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

IMB Dx, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jiwoo Baek	Shinhan Investment Corp.

IMB Dx KOSDAQ:A461030 Stock Report